PD-1/IL-18v bispecific antibody / Galux - LARVOL DELTA

AI-designed PD-1/IL-18v bispecific antibody overcomes PD-1 resistance and drives potent antitumor responses in refractory models (AACR 2026) - "Notably, body weight remained stable over repeated treatments, indicating minimal systemic cytokine toxicity.Collectively, these results demonstrate that the AI-engineered PD-1/IL-18v bispecific antibody elicits provides potent PD-1-dependent IL-18 signaling with tumor specificity while limiting systemic adverse effects. The combination of IL-18BP resistance, diminished IL-18Rα affinity and PD-1-restricted activation creates a compelling basis for next-generation cytokine-based cancer immunotherapy."

Bispecific • Oncology • CD8 • IL15 • IL18 • IL2